Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 19, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details specific share movements within the SmithKline Beecham Employee Benefit Trust ("the Trust") on April 10 and April 11, 2006:
- April 10, 2006: 18 Ordinary shares were transferred from the Trust to a participant in the GlaxoSmithKline Annual Investment Plan.
- April 11, 2006: 761 Ordinary shares were purchased on behalf of participants in the SmithKline Beecham Bonus Investment Plan at a price of GBP 14.92.
- April 11, 2006: 9,518 Ordinary shares were purchased on behalf of participants in the GlaxoSmithKline Annual Investment Plan at a price of GBP 14.92.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the Trust is a discretionary fund for non-US employees and former employees, and that Director Mr. J Heslop holds an interest in the fund shares similarly to other eligible employees.
Investor Verification Points
- Verify the total number of shares purchased by the Trust on April 11, 2006 (10,279 shares total).
- Confirm the transaction price of GBP 14.92 per share against market data for April 11, 2006.
- Review the specific roles of Mr. J Heslop and S M Bicknell (Company Secretary) regarding their disclosure obligations.